Enteric coating composition and method for preparing tablet using same
A water-based enteric coating composition with a specific pH range and additives addresses the stability and aggregation issues of cellulose-based polymers, enabling continuous nozzle spraying and achieving high stability and acid resistance for enteric-coated tablets.
Patent Information
- Application Number
- PCT/KR2024/005892
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-22
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-07
AI Technical Summary
Cellulose-based polymers used in enteric coatings face challenges with low thermal stability, aggregation, and nozzle clogging due to the use of organic solvents and plasticizers, which complicates large-scale industrial coating processes and affects the stability and efficacy of the coating film.
A water-based enteric coating composition with a pH range of 4.8 to 5.3, containing cellulose-based polymers, additives like ammonia water, and plasticizers, which maintains stability and prevents aggregation, allowing for continuous nozzle spraying without clogging, even at high temperatures.
The composition achieves high physical stability and acid resistance, ensuring effective coating without altering the polymer's physical properties, and maintains stability during long-term storage and high-temperature processing, enabling efficient production of enteric-coated tablets with improved thermal stability and reduced aggregation.
Smart Images

Figure KR2024005892_07112024_PF_FP_ABST
Abstract
Description
Composition for enteric coating and method for manufacturing tablets using the same
[0001] The present invention relates to an enteric coating composition comprising a cellulose-based polymer, and a method for producing a pharmaceutical product, a health functional food product, a general food product, etc. using the same.
[0002]
[0003] Cellulose-based polymers are widely used as materials for enteric coatings. While cellulose-based polymers can be dissolved in organic solvents and used as coating solutions, residual organic solvents pose environmental pollution and explosion risks. Therefore, efforts are being made to develop aqueous coating solutions using cellulose-based polymers.
[0004] However, despite the long process times and high temperatures required for moisture evaporation, cellulose-based polymers have low thermal stability, which can lead to uneven coating film formation or cracking. Furthermore, plasticizers are often added to enhance the flexibility required for continuous coating. However, these plasticizers further promote particle adhesion and agglomeration, requiring separate cooling equipment to mitigate this, making them difficult to effectively apply in large-scale industrial coating processes.
[0005] The present inventors have conducted research and made efforts to solve the above problems and have discovered that precise control of pH in an aqueous coating solution effectively improves the stability of the coating solution, and even when additives are used, it is possible to create properties suitable for a high-temperature coating process while maintaining enteric properties. As a result, the present invention has been completed by specifying a method and composition thereof.
[0006]
[0007] The present invention aims to provide an enteric coating composition having reduced aggregation and increased physical stability against heat without changing the physical properties of the polymer.
[0008] The present invention aims to provide a method for manufacturing an enteric tablet by continuous spraying without the problem of nozzle clogging using the above composition.
[0009]
[0010] 1. An enteric coating composition comprising a solvent and a cellulose polymer and having a pH of 4.8 to 5.3.
[0011] 2. A composition for an enteric coating comprising 87 to 93 wt% of a solvent, 5 to 9 wt% of a cellulose polymer, and the remaining additives in the above 1.
[0012] 3. A composition for an enteric coating, wherein the solvent in the above 1 is water, C1-C4 alcohol or a mixture thereof.
[0013] 4. In the above 2, the additive is a composition for an enteric coating, which comprises any one pH adjusting agent selected from the group consisting of ammonia water, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, dibasic sodium phosphate, trolamine, and sodium bicarbonate.
[0014] 5. In the above 2, a composition for enteric coating, wherein the additive comprises any one plasticizer selected from the group consisting of triacetin, triethyl citrate, and propylene glycol.
[0015] 6. In the above 2, the additive is an enteric coating composition comprising any one wetting agent selected from the group consisting of SLS (sodium lauryl sulfate), SDS (sodium dodecyl sulfate), SLES (sodium lauryl ethylene sulfate), sodium oleate, and potassium sorbate.
[0016] 7. In the above 1, the cellulose polymer is any one selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), and cellulose acetate phthalate (CAP), a composition for enteric coating.
[0017] 8. A composition for enteric coating, wherein the wetting agent is contained in an amount of 0.15 to 0.30 wt% in the above 6.
[0018] 9. A composition for an enteric coating having a sedimentation rate of 0 to 20% as measured according to mathematical formula 2 in the above 1:
[0019] [Equation 2]
[0020]
[0021] (In the formula, h0 is the height of the initial solution when 50 g of the composition is taken and placed in a 50 ml glass vial at 25 ° C, h f (This is the height of the sediment measured after leaving it for 15 minutes).
[0022] 10. A method for manufacturing an enteric tablet, comprising the step of continuously spraying a composition of any one of the above 1 to 9 onto a tablet at 35 to 40°C using a nozzle.
[0023] 11. A method for manufacturing an enteric tablet, wherein in the above 10, the nozzle has a diameter of 0.8 to 1.2 mm.
[0024] 12. A method for manufacturing an enteric tablet, wherein the tablet is a lansoprazole tablet in the above 10.
[0025]
[0026] The composition for an enteric coating of the present invention has reduced aggregation and high physical stability against heat without changing the physical properties of a cellulose-based polymer, and can maintain such stability even when a plasticizer is added.
[0027] The composition for an enteric coating of the present invention is suitable for an aqueous coating process. It is particularly suitable for a tablet coating process using a nozzle spray or performed at room temperature or higher.
[0028] The composition for long-acting coating of the present invention has acid resistance and does not decompose at pH 1 to pH 2 (in environments such as the stomach), and can effectively disintegrate and release active ingredients at a pH of about 6.8.
[0029] A preparation coated with the enteric coating composition of the present invention is stable even after long-term storage for 4 weeks or more.
[0030] The method for manufacturing an enteric tablet of the present invention is economical and efficient because it can include a step of continuously coating an enteric coating composition including a cellulose polymer through a nozzle spray or the like.
[0031] The method for manufacturing an enteric tablet of the present invention does not require a separate cooling facility to prevent agglomeration of the composition even when a plasticizer is added.
[0032] The present invention can provide an enteric preparation with high physical stability coated with an enteric coating composition.
[0033]
[0034] Figure 1 shows the coagulation rate according to the pH of the coating solution of the present invention.
[0035] Figure 2 shows the dissolution rate of the lansoprazole tablet of the present invention.
[0036] Figures 3 and 4 show the results of the content test analysis test of the present invention.
[0037] Figures 5 and 6 show the results of impurity tests of the present invention.
[0038] Figures 7 and 8 show the results of an acid absorption experiment of the present invention.
[0039] Figures 9 and 10 show the results of a disintegration experiment at pH 6.8 in the present invention.
[0040] Figures 11 and 12 show the results of the dissolution rate experiment of the present invention.
[0041] Figure 13 shows a photograph showing a nozzle clogging phenomenon in the present invention.
[0042]
[0043] The present invention provides a composition for enteric coating and a method for manufacturing an enteric tablet using the same.
[0044] The present invention provides an aqueous coating solution having high stability and being effectively usable in a nozzle spray coating process by setting the pH of a composition containing a cellulose-based polymer to a specific range.
[0045] The present invention provides an enteric coating composition comprising a solvent and a cellulose polymer and having a pH of 4.8 to 5.3.
[0046] Enteric solubility refers to the property of not being decomposed in the acidic environment of the stomach (pH 1.0 to 3.5) but being ionized and dissolved in the pH environment of the intestine (pH 3.8 to 8.0).
[0047] The solvent may be an aqueous solvent. The aqueous solvent may be, for example, water, a C1-C4 alcohol, or a mixture thereof.
[0048] The cellulose-based polymer used in the enteric coating may be any one selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP) and cellulose acetate phthalate (CAP).
[0049] Hydroxypropyl methylcellulose (HPMC) is a polymer in which cellulose, composed of β units containing three hydroxyl groups, is substituted with a certain proportion of methoxy and hydroxypropoxy groups. In HPMC, the degree of substitution (DS) of methoxy can range from 1.78 to 2.02, and the degree of substitution of hydroxypropoxy can range from 0.23 to 0.41. The degree of substitution refers to the number of functional groups substituted among the hydroxyl groups.
[0050] HPMCAS is a structure containing acetyl and succinic acid esters produced by the reaction of acetic anhydride and succinic anhydride with the hydroxyl groups of the HPMC basic skeleton.
[0051] In the present invention, HPMCAS may be substituted with 5 to 9 wt% of an acetyl group, 14 to 18 wt% of a succinoyl group, 20 to 24 wt% of a methoxyl group, and 5 to 9 wt% of a hydroxypropoxy group. It is soluble in water at a pH of 5.5 or higher.
[0052] In the present invention, the HPMCAS may be in the form of fine particles having an average particle size of about 1 to 10 μm, 3 to 7 μm, or 4 to 6 μm.
[0053] The composition for a long-lasting coating may comprise 87 to 93 wt% of a solvent, 5 to 9 wt% of a cellulose-based polymer, and the remaining additives.
[0054] Additives may include, for example, plasticizers, humectants, and excipients.
[0055] Plasticizers provide flexibility to cellulosic polymer chains, which is useful for film formation, but have the property of reducing the Tg and minimum film formation temperature of the polymer, thereby causing early particle coalescence and agglomeration.
[0056] For this reason, for example, in a spray coating method using a nozzle, the use of a plasticizer may cause premature nozzle clogging, making it difficult to perform a continuous coating process. The composition for an enteric coating of the present invention can perform a coating process without agglomeration even when including additives such as a plasticizer, due to its improved stability.
[0057] The plasticizer may be, for example, triacetin, triethyl citrate (TEC), propylene glycol, or a mixture thereof. The content of the plasticizer is not limited to a specific range. The plasticizer may be included in the composition in an amount of, for example, 0.1 to 3 wt%, 1 to 3 wt%, or 1 to 2 wt%.
[0058] The stability of the enteric coating composition of the present invention can be further improved by including a wetting agent. For example, the wetting agent may be any one selected from the group consisting of sodium lauryl sulfate (SLS), sodium dodecyl sulfate (SDS), sodium lauryl ethylene sulfate (SLES), sodium oleate, and potassium sorbate.
[0059] The content of the humectant is not limited to a specific range. For example, the humectant may be included in the composition in an amount of 0.05 to 0.35 wt%, 0.10 to 0.30 wt%, 0.15 to 0.30 wt%, or 0.20 to 0.30 wt%.
[0060] The excipient may be any one selected from the group consisting of talc, magnesium stearate, polyethylene glycol, magnesium hydroxide, titanium oxide, silicon dioxide, and rhinolenic acid. The content of the excipient is not limited to a specific range. For example, the excipient may be included in the composition at 1 to 3 wt% or 1.5 to 2.5 wt%.
[0061] The composition for an enteric coating of the present invention has a pH of 4.8 to 5.3. By having a pH within this range, the stability of the coating solution containing the cellulose-based polymer is improved. The pH of the composition may be 4.8 to 5.3, 4.8 to 5.2, or 4.9 to 5.1, and in one embodiment, the pH of the composition may be about 5.
[0062] The composition for an enteric coating of the present invention has reduced aggregation and increased physical stability against heat.
[0063] In one embodiment, the composition for a long-lasting coating of the present invention may have a lower coagulation rate at 25°C, 30°C, 35°C, 40°C, and 50°C as measured according to Equation 1 compared to other compositions:
[0064] [Mathematical Formula 1]
[0065]
[0066] (In the formula, W0 represents the initial mass of the composition, and Wt represents the mass of unfiltered aggregates after filtering the composition through a 150 μm sieve at any of the above temperatures).
[0067] In one embodiment, the composition for a long-lasting coating of the present invention may have a coagulation rate of 5 to 10% at 35°C as measured according to mathematical formula 1.
[0068] In one embodiment, the composition for a long-lasting coating of the present invention may have a sedimentation rate of 0 to 20% as measured according to Equation 2:
[0069] [Equation 2]
[0070]
[0071] (In the formula, h0 is the height of the initial solution when 50 g of the composition is taken and placed in a 50 ml glass vial at 25°C, h f (is the height of the sediment measured after leaving it for 15 minutes).
[0072] In one embodiment, the composition for a long-lasting coating of the present invention may have a sedimentation rate measured according to Equation 2 of 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less.
[0073] The composition for a long-lasting coating of the present invention can be effectively applied to an aqueous coating process performed at a relatively high temperature for smooth evaporation of moisture due to its increased thermal stability.
[0074] The composition for an enteric coating of the present invention can maintain continuous thermal stability. The thermal stability can last for at least 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.
[0075] The enteric coating composition of the present invention has a predetermined pH range, thereby improving the stability of the dispersion and exhibiting excellent acid resistance, making it effective for enteric coating. Acid resistance refers to the ability to withstand acid and is necessary for preventing drug degradation in acid-rich gastric juice in enteric coatings.
[0076] The present invention provides a method for manufacturing an enteric tablet, comprising the step of spraying the enteric coating composition of the present invention onto a tablet. The method for manufacturing an enteric tablet of the present invention can provide an enteric-coated tablet with high stability.
[0077] The method for manufacturing an enteric tablet of the present invention may include a step of placing an enteric coating composition into a sprayer having a nozzle at 25 to 45°C or 35 to 40°C and continuously spraying the composition onto the tablet.
[0078] The nozzle may have a diameter of 0.8 mm or more, 0.9 mm or more, or 1 mm or more, and may be in the range of 1.1 mm or less, 1.2 mm or less, 1.3 mm or less, 1.5 mm or less, or 1.7 mm or less. According to the method of the present invention, enteric-coated tablets can be manufactured without nozzle clogging using such fine-diameter nozzles.
[0079] Continuous spraying may be continuous film coating for a thin, uniform coating. This step may be performed using, for example, a pan coater or a fluidized bed coater.
[0080] The continuous injection may be for example, more than 1 hour, more than 2 hours, or more than 2.5 hours, or may be for less than 3 hours, less than 4 hours, or less than 5 hours, but is not limited thereto.
[0081] The method for manufacturing an enteric tablet of the present invention may further include a step of drying the tablet onto which the composition has been sprayed. Drying may be performed by reduced pressure evaporation, spray drying, or natural drying, and may be performed at, for example, 20 to 120°C, 40 to 90°C, or 50 to 60°C.
[0082] The present invention is described in more detail below with examples and experimental examples. These examples and experimental examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention.
[0083]
[0084] Example
[0085] A plasticizer and a wetting agent were added to the solvent and stirred at room temperature for 5 minutes. Then, a cellulose polymer and a plasticizer were added and stirred at room temperature for 1 hour. A pH adjuster was then added to adjust the pH of the composition. The pH of Examples 1 and 2 was adjusted to pH 5.0, taking into account the dissolution characteristics of HPMCAS-LF.
[0086] Classification (weight %) Solvent (water) Cellulose polymer (HPMCAS-LF) Wetting agent (SLS) Plasticizer (triacetin) Excipient (talc) pH regulator HPMCAS 1g Sugar regulator (mg) (25 wt%) Ammonia water) pH Example 189.647.000.211.05 2.10 100 2.5 mg 5.0 Example 289.787.000.07 1.05 2.10 100 2.0 mg 5.0 Comparative Example 189.647.000.211.05 2.10 1000.6 mg 4.5 Comparative Example 289.787.000.07 1.05 2.10 1000.3 mg 4.5 Comparative Example 389.647.000.211.05 2.10 1000.0 mg 4.0 Comparative Example 489.787.000.07 1.05 2.10 1000.0 mg 4.0 HPMCAS-LF (AQOAT) ® , SHIN_ETSU, Japan)Triacetin (SIGMA ALDRICH, Germany)Talc (NIPPON TALC, Japan)Ammonia solution (SAMCHUN, Korea)
[0087]
[0088] Experimental example
[0089] 1. Coating solution coagulation rate test
[0090] 50 g (W0) of the coating solution of each example and comparative example in Table 1 was taken, adjusted to 25°C, 30°C, 35°C, 40°C, and 50°C, filtered through a 150 μm sieve, and the mass (Wt) of the unfiltered aggregates was measured. The aggregation rate was calculated according to mathematical equation 1, and the results are as shown in Fig. 1 and Table 2.
[0091] As shown in Table 2, the coagulation rate of Example 1 was the lowest at 35°C, which is the minimum film-forming temperature (MFFT) of the film. This means that the coagulation rate was lowered and the physical stability against heat during the process was increased by increasing the pH and wetting agent concentration below pH 5.5, which does not cause changes in the physical properties of the polymer.
[0092] Classification 25℃30℃35℃40℃50℃Example 16.1±0.57.1±0.78.1±0.616.0±4.052.3±1.9Example 231.2±1.130.2±0.329.6±1.336.3±3.046.0±0.7Comparative Example 16.2±0.16.9±0.310.6±1.128.8±2.14 0.9±1.1Comparative Example 2 32.1±0.6 35.1±1.3 34.3±0.5 30.8±1.3 44.7±0.6Comparative Example 38.1±0.4 9.0±0.1 18.4±2.7 36.0±1.2 41.1±1.1Comparative Example 4 25.0±0.6 24.8±0.1 32.3±0.8 45.2±0.6 42.2±0.5
[0093]
[0094] 2. Coating solution sedimentation rate test
[0095] 50 g of the coating solution of each example and comparative example in Table 1 was taken and placed in a 50 ml glass vial, and the height of the initial solution (h0) and the height of the sediment (h) were measured after leaving it at 25°C and 30°C for 15 minutes. f ) was confirmed. The sedimentation rate was calculated according to mathematical formula 2, and the results are shown in Table 3.
[0096] As shown in Table 3, Example 1 had the lowest precipitation rate. This means that the precipitation rate can be lowered and the dispersion stability of the coating solution can be increased by increasing the pH and the concentration of the wetting agent at pH 5.5 or lower, which does not cause changes in the physical properties of the polymer.
[0097] Classification 25℃30℃Example 10%8%Example 218%14%Comparative Example 132%22%Comparative Example 232%30%Comparative Example 326%22%Comparative Example 436%34%
[0098]
[0099] 3. Coating solution redispersibility experiment
[0100] 50 g of the coating solution of each example and comparative example in Table 1 was placed in a 50 ml glass vial, left at 25°C and 30°C for 3 hours each, shaken vigorously 30 times, filtered through a 150 μm sieve, and the precipitate was observed with the naked eye. The visual observation criteria are as shown in Table 4 below.
[0101] Grading criteria: Almost nothing remains in body A. Unredispersed aggregates are observed in body B. Unredispersed aggregates and sediments are observed in body C.
[0102] The experimental results are shown in Table 5 below. According to the visual observation criteria, the compositions that showed grade A were Examples 1 and 2 and Comparative Example 1 at 25°C, and Examples 1 and 2 at 30°C. This means that the dispersion stability of the coating solution can be increased by increasing the pH and increasing the wetting agent concentration below pH 5.5, which does not cause changes in the physical properties of the polymer.
[0103] Classification 25℃30℃Example 1AAExample 2AAComparative Example 1ABComparative Example 2BBComparative Example 3ACComparative Example 4BC
[0104]
[0105] 4. Suitability testing of model drugs
[0106] (1) Preparation uniformity test
[0107] Lansoprazole tablets, as shown in Table 6 below, were selected as a model drug, and their formulation uniformity was tested according to the Formulation Uniformity Test Method in the General Test Methods of the Korean Pharmacopoeia. The results are shown in Table 7 below, and both the mass deviation test and the content uniformity test were confirmed to be acceptable with a judgment value of less than 15.
[0108] Usage Ingredient Content (mg / T) Active ingredient: Soprazole (NARAEPLUS, Korea) 30 Excipients: Flowlac 100 (MEGGLE, Germany) 507 Alkalizing agent: Sodium bicarbonate (OCI, Korea) 60 Lubricant: Magnesium stearate (Daesung Pharmaceutical, Korea) 3 Total amount: 600
[0109] n Mass deviation content uniformity 199.7 97.72 96.697.53 105.0 99.84 104.7 102.15 103.3 97.86 102.4 95.87 104.3 98.78 104.0 98.69 99.5 92.2 10104.1 97.2 Judgment value 7.2 13.1 Suitability / failure judgment Suitability / suitability
[0110] The specific test method is as follows. 30 mg of lansoprazole was precisely weighed and placed in a 100 mL volumetric flask, the volume was adjusted to the mark with diluent, and dissolved by sonication for 5 minutes. 2 mL of this solution was placed in a 20 mL volumetric flask, the volume was adjusted to the mark with diluent, and this solution was filtered using a 0.45 μm PVDF filter and placed in a vial to prepare the standard solution. Afterwards, 1 tablet of lansoprazole was placed in a 50 mL volumetric flask, the volume was adjusted to the mark with diluent, and the solution was dissolved by sonication for 15 minutes. 2 mL of this solution was centrifuged at 10,000 RPM, and 1 mL of the supernatant was placed in a 20 mL volumetric flask, the volume was adjusted to the mark with diluent, and this solution was filtered using a 0.45 μm PVDF filter and placed in a vial to prepare the test solution. HPLC analysis conditions were analyzed according to the method described in Table 8 based on 'USP Lansoprazole ASSAY', and are summarized as follows in Mathematical Formula 3.
[0111] [Equation 3]
[0112]
[0113] Detector UV Wavelength 285 nm Column Agilent ZORBAX SB-C18 (5 μm, 4.6 × 250 mm) Mobile phase Acetonitrile: water: triethylamine = 40:60:1 (v / v%) (pH 7.0 with phosphoric acid) Flow rate 1.0 mL / min. Injection volume 10 μL Diluent Acetonitrile: water: triethylamine = 40:60:1 (v / v%) (pH 10.0 with phosphoric acid)
[0114]
[0115] (2) Dissolution test
[0116] A dissolution test was conducted on the lansoprazole tablets in Table 6 according to the dissolution test method of the General Test Methods of the Korean Pharmacopoeia. The results are shown in Fig. 2, and the quantified results are shown in Table 9 below. Since the dissolution rate of the tablets was 80% (Q) or higher within 60 minutes at pH 6.8, it was confirmed that they are suitable as model drug tablets for examining the characteristics of enteric coating films.
[0117] Time (min) 0 1 0 2 0 3 0 4 5 6 0 Dissolution rate (%) 0.0 ± 0.02 8.6 ± 0.14 9.9 ± 2.56 9.5 ± 2.18 3.6 ± 2.29 0.5 ± 1.1
[0118] The specific test method is as follows. 30 mg of lansoprazole was precisely weighed and placed in a 100 mL volumetric flask, then the volume was adjusted to the mark with the diluent and dissolved by sonication for 5 minutes. 1 mL of this solution was taken, 8 mL of the diluent was added, and the solution was filtered using a 0.45 μm PVDF filter. The solution was placed in a vial and used as the standard solution. 5 mL of the eluate was collected, filtered using a 0.45 μm PVDF filter, and then diluted three times with the diluent to prevent SLS precipitation. The solution was placed in a vial and used as the test solution. The HPLC analysis conditions are as shown in Table 8, and the dissolution test was performed under the conditions of Table 10 based on the FDA dissolution method (Lansoprazole tablet).
[0119] Dissolution parameters Conditions Device USP Apparatus 2 (paddle) Stirring 75 rpm Temperature 37±0.5℃ Medium pH 6.8 + SLS 5mM pH 1.2 Medium volume 900 mL Sampling time 10, 20, 30, 45, 60 min
[0120]
[0121] 5. Nozzle spray test according to pH difference
[0122] Based on the above results, coating experiments were conducted at the Daegu-Gyeongbuk Advanced Medical Complex to verify the effectiveness of the composition of the present invention when applied to an actual nozzle spray coating process. Experiments were conducted at pH 4.59 and pH 5.0 using the composition of Example 1 described above.
[0123] Table 11 shows the coating experimental conditions, and spraying proceeded without interruption. No nozzle clogging was observed for the pH 5.0 coating solution over the 150-minute experimental period (wt gain 8.0%). However, nozzle clogging occurred for the pH 4.59 coating solution 30 minutes after the start of coating (Fig. 13), despite the exhaust fan temperature being 1-2°C lower at the time of coating. No separate cooling equipment was used.
[0124] Classification pH 4.59 Coating solution pH 5.00 Coating solution Model Sejong Pharmatech C30 Auto Coating Series Batch size (g) 800g (Placebo 700g / Lansoprazole 100g) Coating fan rpm 13 (10-13) ℃ 40 ~ 50mm Aq - 18.3 ~ 21.4 Exhaust fan rpm 3000 ℃ 35.1 ~ 36.2 35.1 ~ 38.2mm Aq 19 ~ 30 Supply fan rpm 1500 ℃ 78 ~ 89 CMM 3.0 ~ 3.2 m / s 12.8 ~ 13.1 Atom pressure 0.2 Pattern pressure 0.15 ~ 0.20 Cylinder pressure 0.4 Pump speed 7 (5 ~ 7) Continuous time (min) 30 150 Tubing size Inner diameter 4.2 mm Nozzle diameter 1.1 mm
[0125]
[0126] 6. Stability test of coated tablets
[0127] Example 1, Comparative Example 3 and Eudragit, another aqueous enteric coating agent in Table 1 ® The results of the stability test of the long-acting coated tablet (hereinafter referred to as 'Comparative Example 5') were compared.
[0128]
[0129] (1) Manufacturing method
[0130] The manufacturing methods of Example 1 and Comparative Example 3 are as described above. In the case of the composition of Comparative Example 5, distilled water and Eudragit L30D-55 were added to beaker 1 and stirred, distilled water and TEC were added to beaker 2 and stirred for 5 minutes, talc was added and stirred using a mechanical stirrer, and solution 2 was added to solution 1 and stirred for the final time. The composition of the manufactured Comparative Example 5 consists of Eudragit L30D-55: 51.09 w / w%, TEC: 1.53 w / w%, talc: 3.83 w / w%, and water 43.55 w / w%.
[0131] The coating process conditions are as shown in Table 12. The manufactured samples were placed in HDPE bottles with silica gel (10 g) and stored in a chamber. Then, they were tested at intervals of 0 weeks, 2 weeks, 4 weeks, 3 months, and 6 months under accelerated conditions (40±2℃ / relative humidity 75±5%), and at intervals of 0 months, 3 months, 6 months, and 12 months under room temperature conditions (25±2℃ / relative humidity 60±5%).
[0132] Coating parameters Example 1 Comparative Example 3 Comparative Example 5 Internal temperature 34-40℃ 45-52℃ 50-55℃ Product temperature 24-40℃ 35-44℃ 35-47℃ Heater setting 85℃ Spray speed 6-7 g / min Spray pressure 0.3 MPa Drum speed 10 RPM Nozzle diameter 1.55 mm Post-drying 30 minutes
[0133]
[0134] (2) Content test
[0135] The quantitative analysis was performed in the same manner as described in the aforementioned 'Formulation Uniformity of Lansoprazole Tablets'. The HPLC analysis conditions were the same as the aforementioned method based on the 'USP Lansoprazole ASSAY'.
[0136] Drug stability according to coating level did not show significant differences within the range of variation. When lansoprazole tablets were used as a model drug, when comparing Example 1 and Comparative Example 3 under room temperature and accelerated storage conditions, the HPMCAS coating solution showed increased drug stability at pH 5.0 (Figs. 3 and 4).
[0137] Storage conditionsCoating levelStorage periodComparative example 3Example 1Comparative example 5Room temperature6%T0100.0±0.0100.0±0.0100.0±0.0T 3M 93.4±2.597.5±2.796.8±3.4T 6M 94.7±1.099.6±4.999.2±1.4T 12M 100.9±0.597.0±2.796.4±0.48%T0100.0±0.0100.0±0.0100.0±0.0T 3M 90.9±1.198.8±1.998.1±2.5T 6M 96.5±1.298.0±8.4100.0±4.8T 12M 98.1±1.497.6±1.095.4±1.0Acceleration6%T0100.0±0.0100.0±0.0100.0±0.0T 2w 96.4±1.4100.8±4.299.9±2.2T 4w 93.5±3.292.3±1.296.6±2.3T 3M 92.6±0.698.1±4.396.1±2.6T 6M 94.7±0.896.2±5.093.0±1.28%T0100.0±0.0100.0±0.0100.0±0.0T 2w 96.7±2.199.9±0.999.1±0.7T 4w 94.4±1.9100.8±5.698.5±4.1T 3M 91.6±3.099.0±4.497.4±3.1T 6M 93.1±1.995.0±3.298.9±4.2
[0138]
[0139] (3) Flexible material test
[0140] Based on the USP Lansoprazole flexible substances test method, HPLC analysis was performed according to the method described in Table 14 below.
[0141] Detection UV wavelength 285 nm Column Agilent ZORBOX Eclipse XDB-C18 (5 μm, 4.6 × 150 mm) Mobile phase time (min) Solution A (%) Solution B (%) 0 9 0 1 0 4 0 2 0 8 0 5 0 2 0 8 0 5 1 9 0 1 0 6 0 9 0 1 0 Solution A Water Solution B Acetonitrile: water: triethylamine = 160:40:1 (v / v) (pH 7.0 with phosphoric acid) Flow rate 0.8 mL / min Injection volume 40 μL Diluent Methanol: 0.1 N sodium hydroxide = 1:3
[0142] It was confirmed that the total flexible substances in all sample groups under room temperature storage conditions had values less than 1.60%. At 6 months under accelerated storage conditions, the total flexible substances in Comparative Example 3 and Example 1 with a coating level of 8% and Comparative Example 5 with a coating level of 6% had values greater than 1.60%, indicating that when lansoprazole tablets were used as a model drug, the lower the coating level in the HPMCAS group and the higher the coating level in Eudragit L30D-55, the more drug stability was maintained (Figs. 5 and 6).
[0143] Storage conditionsCoating levelStorage periodComparative example 3Example 1Comparative example 5Room temperature6%T00.16±0.040.23±0.030.19±0.04T 3M 0.27±0.110.30±0.030.42±0.02T 6M 0.35±0.140.33±0.070.34±0.03T 12M 0.86±0.160.66±0.220.91±0.058%T00.16±0.030.18±0.020.23±0.07T 3M 0.17±0.060.33±0.040.42±0.03T 6M 0.67±0.310.42±0.040.35±0.02T 12M 0.89±0.050.67±0.070.66±0.03Acceleration6%T00.16±0.040.23±0.030.19±0.04T 2w0.18±0.050.26±0.040.22±0.01T 4w 0.28±0.100.15±0.000.39±0.11T 3M 0.42±0.081.07±0.770.80±0.14T 6M 1.33±0.351.49±0.463.28±0.188%T00.16±0.030.18±0.020.23±0.07T 2w 0.19±0.030.21±0.040.20±0.06T 4w 0.33±0.060.15±0.030.35±0.09T 3M 0.60±0.030.68±0.120.67±0.02T 6M 2.63±0.191.94±0.080.86±0.08
[0144]
[0145] (4) Acid resistance test
[0146] The acid resistance of tablets coated with lansoprazole, a drug sensitive to acid, was confirmed through acid absorption rate. The mass (W0) of lansoprazole enteric-coated tablets was measured, and the mass (W) of the tablets after removing excess moisture on the surface after a 2-hour disintegration test in the first solution was measured. t ) was measured and calculated according to the following mathematical formula 4.
[0147] [Equation 4]
[0148]
[0149] Example 1, which was selected as the optimal composition, had a lower acid absorption rate than Comparative Example 3, and maintained acid resistance without disintegration for 12 months under room temperature storage conditions and 6 months under accelerated storage conditions (Figs. 7 and 8).
[0150] Storage conditionsCoating levelStorage periodComparative example 3Example 1Comparative example 5Room temperature6%T09.7±1.54%6.4±0.54%1.7±0.05%T 3M 14.2±1.69%10.3±2.87%3.4±2.64%T 6M 11.5±0.86%13.5±1.66%2.0±0.04%T 12MDisintegration 14.1±0.66%2.0±0.09%8%T08.5±0.88%5.7±0.15%1.6±0.25%T 3M 10.6±1.93%5.1±1.07%1.4±0.05%T 6M 13.4±1.80%8.7±1.13%1.4±0.09%T 12M 10.2±2.53%6.7±0.53%1.9±0.13%Acceleration6%T09.7±1.54%6.4±0.54%1.7±0.05%T 2w 10.9±3.61%6.9±1.52%1.5±0.23%T 4w 10.4±0.69%9.6±1.10%1.7±0.44%T 3M 12.3±0.97%3.7±0.31%6.4±1.95%T 6M Disintegration Disintegration Disintegration 8%T08.5±0.88%5.7±0.15%1.6±0.25%T 2w 7.3±1.31%5.3±1.41%1.6±0.06%T 4w 9.8±1.29%4.9±0.95%1.7±1.29%T 3M 15.2±1.03% disintegration 1.4±0.59%T 6M Disintegration rate 1.5±0.04%
[0151]
[0152] (5) Disintegration test
[0153] The test was conducted according to the disintegration test method of the Korean Pharmacopoeia, and it was confirmed that all samples did not disintegrate by testing in the first solution (pH 1.2) for 120 minutes according to the operating method for general release preparations, and disintegration was determined by testing in the second solution (pH 6.8) for 60 minutes according to the operating method for general release preparations. No auxiliary plate was used.
[0154] All tablets, including Example 1, did not disintegrate in the first solution (pH 1.2), but all disintegrated completely within 1 hour in the second solution (pH 6.8). The disintegration test results are shown in Tables 17 and 18 below.
[0155] As a result of the disintegration test at pH 1.2, Comparative Example 3 disintegrated as the coating level decreased after 12 months of storage at room temperature, but Example 1 and Comparative Example 5 did not disintegrate in all sample groups regardless of the coating level.
[0156] As a result of the disintegration test at pH 6.8, it was confirmed that Example 1 and Comparative Example 3 disintegrated faster than Comparative Example 5 (Figs. 9 and 10).
[0157] Disintegration test results at pH 1.2 Storage conditions Coating level Storage period Comparative example 3 Example 1 Comparative example 5 Room temperature 6% T0 Suitable Suitable Suitable T 3M Suitable Suitable Suitable T 6M Suitable Suitable Suitable T 12M InadequateSuitableSuitable8%T0SuitableSuitableT 3M Suitable Suitable Suitable T 6M Suitable Suitable Suitable T 12M Suitable Suitable Suitable Acceleration 6% T0 Suitable Suitable Suitable T 2w Suitable Suitable Suitable T 4w Suitable Suitable Suitable T 3M Suitable Suitable Suitable T 6M InadequateInadequateInadequate8%T0SuitableSuitableSuitableT 2w Suitable Suitable Suitable T 4w Suitable Suitable Suitable T 3M Suitable Unsuitable Suitable T 6M InappropriateInappropriateSuitable
[0158] Disintegration test results at pH 6.8 Storage conditions Coating level Storage period Comparative example 3 Example 1 Comparative example 5 Room temperature 6%T0 41' 16''±10.6% 41' 24''±1.2% 48' 31''±4.1%T 3M 35' 30''±1.3%36' 04''±5.5%44' 18''±8.9%T 6M 32' 25''±5.3%38' 26''±1.3%44' 24''±1.0%T 12M N / A39' 24''±1.1%48' 05''±1.8%8%T046' 22''±2.8%46' 01''±5.3%50' 22''±3.3%T 3M 41' 50''±5.5%38' 05''±2.1%48' 24''±3.4%T 6M37' 07''±2.3%40' 24''±3.1%46' 45''±0.9%T 12M 39' 02''±5.5%41' 25''±2.9%50' 45''±1.0%Acceleration6%T041' 16''±10.6%41' 24''±1.2%48' 31''±4.1%T 2w 36' 27''±5.1%43' 15''±2.9%52' 17''±1.8%T 4w 39' 23''±6.9%39' 53''±3.1%48' 19''±4.1%T 3M 34' 36''±8.9%33' 29''±3.7%39' 10''±4 .6%T 6M N / AN / AN / A8%T046' 22''±2.8%46' 01''±5.3%50' 22''±3.3%T 2w 45' 30''±3.2%48' 25''±4.1%56' 02''±3.8%T 4w 44' 37''±1.7%44' 39''±0.8%54' 22''±3.5%T 3M 44' 39''±3.9%N / A52' 53''±4.7%T 6M N / AN / A44' 42''±2.8%N / A: Group of specimens disintegrated during the first liquid treatment process
[0159]
[0160] (6) Dissolution test
[0161] The dissolution test was conducted according to the dissolution test method of the General Test Methods of the Korean Pharmacopoeia, and is summarized in Table 19 below.
[0162] Dissolution parameters Conditions Device USP Apparatus 2 (paddle) Stirring 75 rpm Temperature 37±0.5℃ Medium pH 6.8 + SLS 5mM pH 1.2 Medium volume 900 mL Sampling time (min) 10, 20, 30, 45, 60 (pH 6.8), 60, 120 (pH 1.2)
[0163] Test results showed that all tablets, regardless of coating level, did not exceed 10% dissolution rate from the first solution within 60 minutes at one month under accelerated conditions.
[0164] In the second liquid, some of the sample groups of Comparative Example 3 and Comparative Example 4 at 6 months of room temperature storage conditions with a coating level of 8% had low dissolution rates and were judged as unsuitable, but Example 1 was suitable at 80% (Q) or higher within 60 minutes regardless of the coating level.
[0165] The results of the dissolution test are shown in Figs. 11 and 12 and Tables 20 and 21 below. It was confirmed that Comparative Example 5 was partially unsuitable because its dissolution rate was lower than that of the compositions of Example 1 and Comparative Example 3.
[0166] Dissolution rate at pH 1.2 Storage conditions Coating level Storage period Comparative example 3 Example 1 Comparative example 5 Room temperature 6% T0N / AN / AN / AT 3M N / AN / AN / AT 6M N / AN / AN / AT 12M N / AN / AN / A8%T0N / AN / AN / AT 3M N / AN / AN / AT 6M N / AN / AN / AT 12M N / AN / AN / AAcceleration6%T0BLOQBLOQBLOQT 2w BLOQBLOQBLOQT 4w BLOQBLOQBLOQT 3M N / AN / AN / AT 6M N / AN / AN / A8%T0BLOQBLOQBLOQT 2w BLOQBLOQBLOQT 4w BLOQBLOQBLOQT 3M N / AN / AN / AT 6M N / AN / AN / A
[0167] Dissolution rate at pH 6.8 (5 nM SLS) Storage conditions Coating level Storage period Comparative example 3 Example 1 Comparative example 5 Room temperature 6% T 0 9 6.8 ± 9.2% 8 5.3 ± 1.6% 8 3.6 ± 2.2% T 3M 86.4±3.8%85.8±1.2%82.9±8.3%T 6M 81.9±2.6%83.1±1.7%81.1±1.0%T 12M 86.3±5.0%88.5±4.6%85.8±1.0%8%T085.3±6.3%85.1±1.0%76.5±5.5%T3M 84.6±7.9%81.8±6.2%79.2±3.0%T 6M 78.6±5.2%83.4±2.4%74.9±1.0%T 12M 85.5±2.7%96.0±1.8%77.8±1.0%가속6%T096.8±9.2%85.3±1.6%83.6±2.2%T 2w 90.2±0.6%90.0±2.3%88.3±0.4%T 4w 85.6±3.3%87.9±0.8%83.9±1.4%T 3M 85.0±6.8%91.2±2.0%92.0±11.8%T 6M 82.5±2.3%93.2±0.5%89.1±0.5%8%T085.3±6.3%85.1±1.0%76.5±5.5%T 2w 83.5±0.4%88.3±2.0%79.4±2.3%T 4w 87.0±1.1%85.1±3.3%79.6±5.8%T 3M 103.5±3.1%86.3±4.2%83.3±4.7%T 6M 80.6±1.4%89.8±0.1%79.3±0.0%
Claims
1. An enteric coating composition comprising a solvent and a cellulose polymer and having a pH of 4.8 to 5.
3.
2. A composition for an enteric coating comprising 87 to 93 wt% of the solvent, 5 to 9 wt% of the cellulose polymer, and the remaining additives according to claim 1.
3. A composition for an enteric coating according to claim 1, wherein the solvent is water, C1-C4 alcohol or a mixture thereof.
4. A composition for an enteric coating, wherein the additive in claim 2 comprises any one pH adjusting agent selected from the group consisting of ammonia water, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, dibasic sodium phosphate, trolamine, and sodium bicarbonate.
5. A composition for an enteric coating, wherein the additive comprises any one plasticizer selected from the group consisting of triacetin, triethyl citrate, and propylene glycol, in claim 2.
6. A composition for enteric coating, wherein the additive according to claim 2 comprises any one wetting agent selected from the group consisting of sodium lauryl sulfate (SLS), sodium dodecyl sulfate (SDS), sodium lauryl ethylene sulfate (SLES), sodium oleate, and potassium sorbate.
7. A composition for an enteric coating, wherein in claim 1, the cellulose polymer is any one selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), and cellulose acetate phthalate (CAP).
8. A composition for an enteric coating, wherein the wetting agent is contained in an amount of 0.15 to 0.30 wt% according to claim 6.
9. A composition for an enteric coating, wherein the precipitation rate measured according to the following mathematical formula 2 in claim 1 is 0 to 20%: [Equation 2] (In the formula, h0 is the height of the initial solution when 50 g of the composition is taken and placed in a 50 ml glass vial at 25°C, h f (This is the height of the sediment measured after leaving it for 15 minutes).
10. A method for manufacturing an enteric tablet, comprising the step of continuously nozzle-injecting the composition of any one of claims 1 to 9 into the tablet at 35 to 40°C.
11. A method for manufacturing an enteric tablet according to claim 10, wherein the nozzle has a diameter of 0.8 to 1.2 mm.
12. A method for manufacturing an enteric tablet according to claim 10, wherein the tablet is a lansoprazole tablet.
Citation Information
Patent Citations
Compound capsule and preparation method thereof
CN102091084A
Enteric coated pharmaceutical tablet and method ofmanufacturing
KR100535954B1
Apparatus and method for classifying documents
KR102144464B1
Composition for enteric hard capsule and enteric hard capsule prepared using the composition
US20150080479A1
Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6228400B1
